FDA Safety Communication: Biotin Supplements May Result in Falsely Low Troponin Results
10 Nov, 2019 | 13:43h | UTCCommentary: FDA Updates Warning on Biotin Interfering with Lab Results – NEJM Journal Watch (free)
“…the FDA is particularly concerned about biotin interference causing a falsely low result for troponin, a clinically important biomarker to aid in the diagnosis of heart attacks, which may lead to a missed diagnosis and potentially serious clinical implications. The FDA continues to receive adverse events reports indicating biotin interference caused falsely low troponin results.”